Johnson & Johnson scientists have countered an affirmation in a medical journal that the design of their vaccine against COVID-19, which is similar AstraZeneca’s, may explain why both the vaccines have been tied to very rare brain blood clots in some of the individuals who have received the vaccines.

While the U.S. FDA is examining this design used in both the vaccines to ascertain if it accounts for the risk, J&J scientists, in a letter in the New England Journal of Medicine, opposed a case report published by Kate Lynn-Muir and colleagues at the University of Nebraska, alleging that the rare blood clots could be associated with adenoviral vector vaccines… (Reuters, April 16, 2021)